SIBO — Small Intestinal Bacterial Overgrowth — has gone from obscure GI diagnosis to wellness industry phenomenon in under a decade. The truth is somewhere between "ignored by conventional medicine" and "diagnosed in everyone with IBS." Here's what the research actually shows.
SIBO is defined as an abnormal proliferation of bacteria in the small intestine — an area that should have relatively few bacteria (compared to the colon). The bacteria ferment carbohydrates before they can be absorbed, producing hydrogen and methane gas. This fermentation causes bloating, distension, altered motility, and — via gut-brain axis signaling — brain fog and mood dysregulation.
No symptom is SIBO-specific, but the constellation is recognizable:
SIBO symptoms overlap almost completely with IBS — current research suggests that 30–85% of IBS patients may have SIBO. The practical implication: if you've been told you have IBS and have classic symptoms, SIBO testing is reasonable before accepting a functional diagnosis.
The Hydrogen + Methane Breath Test (HMBT) is the standard SIBO diagnostic — you ingest a sugar (lactulose or glucose), and your breath is measured for hydrogen and methane over 2–3 hours. Bacteria fermenting the sugar produce detectable gases.
Glucose breath test is more specific (fewer false positives) but misses SIBO in the distal small intestine — glucose is fully absorbed in the proximal small intestine, so bacteria further downstream won't be detected. Lactulose breath test reaches the entire small intestine but produces more false positives — lactulose itself slows motility, and the arrival of lactulose in the colon can be misread as SIBO.
The North American Consensus (2017) recommends lactulose with a 20 ppm rise above baseline within 90 minutes as diagnostic. Many labs use different cut-offs, which is part of why SIBO diagnosis is contested.
Previously called "methane-dominant SIBO," now correctly classified as IMO — because methane-producing organisms (Archaea, not bacteria) colonize the colon, not the small intestine. IMO presents differently: predominant constipation, slower transit time, and different treatment (neomycin + rifaximin combination required, not rifaximin alone).
Non-absorbable antibiotic that stays in the gut; minimal systemic effects and doesn't disrupt colonic microbiome significantly. Dose: 400–550mg three times daily for 14 days (hydrogen SIBO). For IMO: rifaximin 550mg + neomycin 500mg, both 3x/day for 14 days. Eradication rate ~70% for hydrogen SIBO; ~87% for the combination IMO protocol.
Limitation: Expensive without insurance coverage (~$1,500/course in the US). Requires a prescription. Does not address root causes — relapse risk is high without concurrent motility/acid work.
A 2014 study published in Global Advances in Health and Medicine directly compared herbal antimicrobials to rifaximin in SIBO patients. The herbal protocol achieved equivalent eradication rates (~68% vs. ~70%) and was significantly cheaper. Standard protocol: berberine (500mg 3x/day) + oregano oil (200mg 2x/day) + allicin (450mg 3x/day) for 4 weeks.
Berberine on Amazon →Pre-digested liquid nutrition — amino acids, glucose, MCT oils — that is absorbed entirely in the proximal small intestine, starving bacteria of fuel. A 2004 study found 91% normalization of breath tests after 2 weeks. The trade-off: difficult to tolerate (unflavored versions taste terrible), expensive (~$50/day), and carries risk of muscle loss and caloric insufficiency if not done carefully.
SIBO relapse within 9 months occurs in ~44% of treated patients who don't address underlying causes. Treatment without root cause investigation is treating symptoms, not disease.
Stomach acid is the first-line defense against bacterial colonization of the small intestine. People on PPIs (proton pump inhibitors) have 7x higher SIBO rates than controls. PPI use should be reviewed in anyone with recurrent SIBO. Natural interventions: betaine HCl with pepsin (for low acid); apple cider vinegar before meals (mild evidence).
The MMC is the "housekeeper wave" — a cyclic contraction pattern during fasting that sweeps bacteria from the small intestine into the colon. Stress, hypothyroidism, and diabetes all impair MMC function. Pro-kinetic agents (low-dose naltrexone, ginger, iberogast) can restore MMC function and are often critical for preventing relapse.
Prior abdominal surgeries, endometriosis, and Crohn's disease can cause adhesions that create bacterial "pockets" in the small intestine — sheltered from the MMC sweep. These cases often require a different treatment approach and may relapse regardless of antimicrobial treatment.
As an Amazon Associate, GutCode earns from qualifying purchases made through links on this page. This does not affect the price you pay.